AnalystBook Research · Company Intelligence

Calumet, Inc. /DE

CLMTNasdaq

Built from Calumet, Inc. /DE's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Calumet, Inc. /DE: Revenue declined 1.2% to $4.137B from $4.189B. Net loss narrowed to $33.8M from $222M. Free cash flow turned positive at $56.6M from a $123M outflow. Operating margin expanded 244 bps to 2.63%. Calumet, Inc. /DE's annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue declined 1.2% to $4.1BWatch
  • Profitability — Net loss narrowed to $33.8MOK
  • Cash flow — Free cash flow turned positive at $56.6M from a $123M outflowOK
  • Margins — Operating margin expanded 244 bps to 2.6%OK
  • Accounting — Distress-range screen needs contextWatch
  • Insiders — 0 purchases and 3 salesWatch

Business

Our ability to produce numerous specialty products allows us to ship products between our facilities for product upgrading in order to meet customer specifications. ● We are a Leader in North America’s Energy Transition .

Where the revenue comes from

Fiscal 2025, as Calumet, Inc. /DE reports it. History and quarterly detail are in the app.

  • Specialty Products and Solutions$2.7B
  • Montana Renewables$1.2B
  • Performance Brands$311.5M

Leadership changes

From Calumet, Inc. /DE's own filings, the day they're filed.

  • Jennifer G. Straumins · Directors · departureeff. 2026-03-23
  • David A. Lunin · Chief Financial Officer · departureeff. 2025-05-21
  • David Lunin · principal accounting officer · appointmenteff. 2025-04-15

Latest filings

  • 8-K · Company announcement2026-09-15
  • 8-K · Company announcement2026-09-01
  • 8-K · Company announcement2026-08-07
  • 10-Q · Quarterly report2026-08-07
  • 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Calumet, Inc. /DE, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.